Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different hepatitis C virus dynamics of free-virions and immune-complexes after initiation of interferon-alpha in patients with chronic hepatitis C.

Journal of hepatology - 1 Dec 2003

Fujita Naoki, Kaito Masahiko, Takeo Masaki, Horiike Shinichiro, Tanaka Hideaki, Ikoma Jiro, Watanabe Shozo, Adachi Yukihiko

Abstract excerpt

BACKGROUND/AIMS: To elucidate the mechanisms of action of interferon (IFN) against hepatitis C virus (HCV), we studied the serum HCV dynamics of free-virions (FV) and immune-complexes (IC) in patients treated with IFN. METHODS: FV and IC were separated by immunoprecipitation using anti-human immunoglobulin and quantified serially using real-time detection-polymerase chain reaction. RESULTS: Initially [1st phase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Antibody Complex
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Viral Load

Share to Virion

Source

Identifiers

PMID: 14642620
DOI: 10.1016/s0168-8278(03)00472-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different hepatitis C virus dynamics of free-virions and immune-complexes after initiation of interferon-alpha in patients with chronic hepatitis C.PMID 14642620Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response.Semantic proximity Read ↗

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.Semantic proximity Read ↗

Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus.Semantic proximity Read ↗

Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics.Semantic proximity Read ↗

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.Semantic proximity Read ↗

Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month.Semantic proximity Read ↗

Nonimmune complexed HCV RNA titer in serum as a predictor of interferon response in patients with chronic hepatitis C.Semantic proximity Read ↗

Triphasic decline of hepatitis C virus RNA during antiviral therapySemantic proximity Read ↗

Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices.Semantic proximity Read ↗

Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.